KAS
LCTX icon

Kestra Advisory Services’s Lineage Cell Therapeutics LCTX Stock Holding History

Kestra Advisory Services’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.6K Buy
37,847
+10,000
+36% +$13.8K ﹤0.01% 3213
2026
Q1 		$44K Buy
27,847
+100
+0.4% +$169 ﹤0.01% 3065
2025
Q4 		$46.3K Buy
27,747
+17,647
+175% +$30.5K ﹤0.01% 3994
2025
Q3 		$17.1K Buy
+10,100
New +$12K ﹤0.01% 2886

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Kestra Advisory Services's LCTX Position: Q2 2026 in Review

Kestra Advisory Services increased its Lineage Cell Therapeutics (LCTX) stake by 36% in Q2 2026, buying an estimated $13.8K and bringing the position to 37,847 shares worth $49.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3213.

Kestra Advisory Services first reported a position in LCTX in Q3 2025 and has held it in 4 quarters since. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • Kestra Advisory Services held 37,847 shares of Lineage Cell Therapeutics worth $49.6K as of Q2 2026.
  • Kestra Advisory Services bought 10,000 Lineage Cell Therapeutics shares in Q2 2026, an estimated $13.8K.
  • Lineage Cell Therapeutics made up ﹤0.01% of Kestra Advisory Services's portfolio in Q2 2026, its #3213 holding.
  • Kestra Advisory Services first reported a position in Lineage Cell Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Kestra Advisory Services's 13F filing for Q2 2026, filed 28 Jul 2026.